Xeris Biopharma Holdings, Inc.
XERS
$6.96
-$0.22-3.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 74.38M | 71.54M | 60.12M | 60.10M | 54.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 74.38M | 71.54M | 60.12M | 60.10M | 54.27M |
| Cost of Revenue | 11.00M | 11.90M | 8.73M | 9.48M | 13.59M |
| Gross Profit | 63.38M | 59.64M | 51.39M | 50.62M | 40.68M |
| SG&A Expenses | 46.46M | 44.39M | 44.02M | 34.04M | 44.97M |
| Depreciation & Amortization | 2.71M | 2.71M | 2.71M | 2.71M | 2.71M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.65M | 67.06M | 63.21M | 52.32M | 67.16M |
| Operating Income | 6.73M | 4.48M | -3.09M | 7.78M | -12.89M |
| Income Before Tax | 621.00K | -1.93M | -9.22M | -5.11M | -19.06M |
| Income Tax Expenses | -- | -- | -- | 0.00 | -3.32M |
| Earnings from Continuing Operations | 621.00K | -1.93M | -9.22M | -5.11M | -15.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 621.00K | -1.93M | -9.22M | -5.11M | -15.74M |
| EBIT | 6.73M | 4.48M | -3.09M | 7.78M | -12.89M |
| EBITDA | 9.78M | 7.52M | -65.00K | 10.80M | -9.88M |
| EPS Basic | 0.00 | -0.01 | -0.06 | -0.03 | -0.11 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.04 | 0.00 | -0.08 |
| EPS Diluted | 0.00 | -0.01 | -0.06 | -0.03 | -0.11 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.04 | 0.00 | -0.08 |
| Average Basic Shares Outstanding | 163.65M | 159.46M | 152.45M | 149.09M | 148.99M |
| Average Diluted Shares Outstanding | 177.62M | 159.46M | 152.45M | 149.09M | 148.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |